Outcomes of patients with myocardial infarction and cardiogenic shock treated with culprit vessel-only versus multivessel primary PCI

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43925980" target="_blank" >RIV/00064173:_____/24:43925980 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/24:00084599 RIV/00216224:14110/24:00135367 RIV/00216208:11120/24:43925980 RIV/00216208:11140/24:10467143 a 7 dalších

Výsledek na webu

<a href="https://doi.org/10.1016/j.hjc.2023.08.009" target="_blank" >https://doi.org/10.1016/j.hjc.2023.08.009</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.hjc.2023.08.009" target="_blank" >10.1016/j.hjc.2023.08.009</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Outcomes of patients with myocardial infarction and cardiogenic shock treated with culprit vessel-only versus multivessel primary PCI

Popis výsledku v původním jazyce

INTRODUCTION AND OBJECTIVES: Multivessel primary percutaneous coronary intervention (pPCI) is still often used in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS). The study aimed to compare the characteristics and prognosis of patients with CS-STEMI and multivessel coronary disease (MVD) treated with culprit vessel-only pPCI or multivessel pPCI during the initial procedure. MATERIAL AND METHODS: From 2016 to 2020, 23,703 primary PCI patients with STEMI were included in a national all-comers registry of cardiovascular interventions. From them, 1,213 (5.1%) patients had cardiogenic shock and MVD at admission to the hospital. Initially, 921 (75.9%) patients were treated with CV-pPCI and 292 (24.1%) with MV-pPCI. RESULTS: Patients with 3-vessel disease and left main disease had a higher probability of being treated with MV-pPCI than patients with 2-vessel disease and patients without left main disease (28.5% vs. 18.6%; p &lt; 0.001 and 37.7% vs. 20.6%; p &lt; 0.001). Intra-aortic balloon pump, extracorporeal membrane oxygenation (ECMO), and other mechanical circulatory support systems were more often used in patients with MV-pPCI. 30-day and 1-year all-cause mortality rates were similar in the CV-pPCI and MV-pPCI groups (Odds ratio, 1.01; 95% CI 0.77 to 1.32; p = 0.937 and 1.1; 95% CI 0.84 to 1.44; p = 0.477). The presence of 3-vessel disease and the use of ECMO were the strongest adjusted predictors of 30-day and 1-year mortality. CONCLUSIONS: Our data from an extensive all-comers registry suggests that selective use of MV-pPCI does not increase the all-cause mortality rate in patients with CS-STEMI and MVD compared to CV-pPCI.

Název v anglickém jazyce

Outcomes of patients with myocardial infarction and cardiogenic shock treated with culprit vessel-only versus multivessel primary PCI

Popis výsledku anglicky

INTRODUCTION AND OBJECTIVES: Multivessel primary percutaneous coronary intervention (pPCI) is still often used in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS). The study aimed to compare the characteristics and prognosis of patients with CS-STEMI and multivessel coronary disease (MVD) treated with culprit vessel-only pPCI or multivessel pPCI during the initial procedure. MATERIAL AND METHODS: From 2016 to 2020, 23,703 primary PCI patients with STEMI were included in a national all-comers registry of cardiovascular interventions. From them, 1,213 (5.1%) patients had cardiogenic shock and MVD at admission to the hospital. Initially, 921 (75.9%) patients were treated with CV-pPCI and 292 (24.1%) with MV-pPCI. RESULTS: Patients with 3-vessel disease and left main disease had a higher probability of being treated with MV-pPCI than patients with 2-vessel disease and patients without left main disease (28.5% vs. 18.6%; p &lt; 0.001 and 37.7% vs. 20.6%; p &lt; 0.001). Intra-aortic balloon pump, extracorporeal membrane oxygenation (ECMO), and other mechanical circulatory support systems were more often used in patients with MV-pPCI. 30-day and 1-year all-cause mortality rates were similar in the CV-pPCI and MV-pPCI groups (Odds ratio, 1.01; 95% CI 0.77 to 1.32; p = 0.937 and 1.1; 95% CI 0.84 to 1.44; p = 0.477). The presence of 3-vessel disease and the use of ECMO were the strongest adjusted predictors of 30-day and 1-year mortality. CONCLUSIONS: Our data from an extensive all-comers registry suggests that selective use of MV-pPCI does not increase the all-cause mortality rate in patients with CS-STEMI and MVD compared to CV-pPCI.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hellenic Journal of Cardiology

ISSN

1109-9666

e-ISSN

2241-5955

Svazek periodika

76

Číslo periodika v rámci svazku

March-April

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

10

Strana od-do

1-10

Kód UT WoS článku

001227067900001

EID výsledku v databázi Scopus

2-s2.0-85170086758